Request Info Medical Affairs Prescribing Information Important Safety Information Visit Patient Site

Administration options let you plan treatment around your patients’ lives

Once you’ve chosen dosing that fits your patient’s needs and preferences, it’s time to select administration options and initiate therapy.

Jump to:

Initiating Therapy
Administering Hizentra

See how simple self-administration can be with Hizentra

Self-infusing with Hizentra prefilled syringes

Download our step-by-step guide to pump administration

Self-infusing with Hizentra vials

Why dosing flexibility matters for patients

Initiate therapy 1 week after last IVIg infusion

Initiate therapy 1 week after last IVIg infusion timeline
  • Lowest recommended subcutaneous dose is 0.2 g/kg body weight per week*
    • — A dose of 0.4 g/kg body weight per week was also safe and effective
  • If CIDP symptoms worsen on 0.2 g/kg, consider increasing to 0.4 g/kg per week†
  • Most patients remained relapse-free on either dosing option, with the 0.4 g/kg dose showing a lower rate of relapse1‡§
*Administered in 1 or 2 sessions over 1 or 2 consecutive days.
†Administered in 2 sessions per week over 1 or 2 consecutive days.
‡CIDP relapse was defined as a ≥1-point increase in adjusted Inflammatory Neuropathy Cause and Treatment [INCAT] score compared with baseline.
§In the PATH Study, no statistically significant difference was found between the low-dose and the high-dose groups. In the PATH Extension Study, statistical tests between the low and high doses were not conducted.

Convenient self-administration for CIDP

Infusion Parameters‖
1st Infusion
Subsequent Infusions
CIDP
Weekly
Volume (g/site)
Rate (g/hr/site)
≤4
≤4
≤10
≤10
‖As tolerated.

Convenient self-administration for CIDP

Infusion Parameters‖
1st Infusion
Subsequent Infusions
CIDP Weekly
Volume (g/site)
Rate (g/hr/site)
≤4
≤4
≤10
≤10
‖As tolerated.

Administering Hizentra therapy

Hizentra should be administered subcutaneously (SC) only. Do not administer intravenously. Hizentra can be administered weekly for CIDP in 1 or 2 sessions over 1 or 2 consecutive days, using an infusion pump and relatively small needle(s).

Recommended Infusion Sites

recommended infusion sites
  • A Hizentra dose may be infused into multiple injection sites. Use up to 8 sites simultaneously per infusion. More than one infusion device can be used. Infusion sites should be at least 2 inches apart. Change the actual site of infusion with each administration
  • SC needles are smaller than IV needles. Depending on a patient’s size and weight, a needle as short as 4 mm or as long as 14 mm can be used
SHARE Nurse training for CIDP

Dosing

Explore tools and information to help you tailor treatment to individual patient needs

Dosing calculator

SHARE Nurse Training program

Sign up for free online administration training—and become a SHARE Hizentra administration specialist

Start SHARE training

Managing infusions

Information and resources are available to help patients manage their ongoing administration of Hizentra

Managing therapy
Reference: 1. van Schaik IN, Orell M, Bril V, et al. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP. Neurol Neuroimmunol Neuroinflamm. 2019;6:e590.
acuity
You are now leaving the current website.

Do you want to continue?

No Yes